CN103313974A - 苯并咪唑呼吸道合胞病毒抑制剂 - Google Patents

苯并咪唑呼吸道合胞病毒抑制剂 Download PDF

Info

Publication number
CN103313974A
CN103313974A CN2011800602778A CN201180060277A CN103313974A CN 103313974 A CN103313974 A CN 103313974A CN 2011800602778 A CN2011800602778 A CN 2011800602778A CN 201180060277 A CN201180060277 A CN 201180060277A CN 103313974 A CN103313974 A CN 103313974A
Authority
CN
China
Prior art keywords
compound
compound according
compounds
cycloalkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800602778A
Other languages
English (en)
Chinese (zh)
Inventor
L.P.库伊曼斯
S.D.德明
胡丽丽
T.H.M.容克斯
P.J-M.B.拉博瓦松
A.塔里
S.M.H.旺德维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen R&D Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103313974(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R&D Ireland ULC filed Critical Janssen R&D Ireland ULC
Priority to CN201710103106.8A priority Critical patent/CN107417683A/zh
Publication of CN103313974A publication Critical patent/CN103313974A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2011800602778A 2010-12-16 2011-12-16 苯并咪唑呼吸道合胞病毒抑制剂 Pending CN103313974A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710103106.8A CN107417683A (zh) 2010-12-16 2011-12-16 苯并咪唑呼吸道合胞病毒抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10195467.5 2010-12-16
EP10195467 2010-12-16
PCT/EP2011/073008 WO2012080446A1 (en) 2010-12-16 2011-12-16 Benzimidazole respiratory syncytial virus inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710103106.8A Division CN107417683A (zh) 2010-12-16 2011-12-16 苯并咪唑呼吸道合胞病毒抑制剂

Publications (1)

Publication Number Publication Date
CN103313974A true CN103313974A (zh) 2013-09-18

Family

ID=43875271

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800602778A Pending CN103313974A (zh) 2010-12-16 2011-12-16 苯并咪唑呼吸道合胞病毒抑制剂
CN201710103106.8A Pending CN107417683A (zh) 2010-12-16 2011-12-16 苯并咪唑呼吸道合胞病毒抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710103106.8A Pending CN107417683A (zh) 2010-12-16 2011-12-16 苯并咪唑呼吸道合胞病毒抑制剂

Country Status (30)

Country Link
US (1) US8865705B2 (https=)
EP (1) EP2651903B1 (https=)
JP (1) JP6005656B2 (https=)
KR (1) KR101876240B1 (https=)
CN (2) CN103313974A (https=)
AR (1) AR085203A1 (https=)
AU (1) AU2011343255B2 (https=)
BR (1) BR112013012137A2 (https=)
CA (1) CA2821999C (https=)
CL (1) CL2013001713A1 (https=)
CY (1) CY1117751T1 (https=)
DK (1) DK2651903T3 (https=)
EA (1) EA022972B1 (https=)
ES (1) ES2576180T3 (https=)
HK (1) HK1247616A1 (https=)
HR (1) HRP20160650T1 (https=)
HU (1) HUE029247T2 (https=)
IL (1) IL225640A (https=)
MX (1) MX340030B (https=)
MY (1) MY156641A (https=)
NZ (1) NZ609450A (https=)
PH (1) PH12013500796A1 (https=)
PL (1) PL2651903T3 (https=)
PT (1) PT2651903E (https=)
SG (1) SG190766A1 (https=)
SI (1) SI2651903T1 (https=)
TW (1) TWI530495B (https=)
UA (1) UA112298C2 (https=)
WO (1) WO2012080446A1 (https=)
ZA (1) ZA201304424B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI501967B (zh) * 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) * 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
US20150111868A1 (en) 2012-06-15 2015-04-23 Jansen R&D Ireland Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
WO2013186334A1 (en) * 2012-06-15 2013-12-19 Janssen R&D Ireland 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
ES2600318T3 (es) * 2012-07-10 2017-02-08 F. Hoffmann-La Roche Ag Nuevos indazoles para el tratamiento y profilaxis de infección por virus sincitial respiratorio
MY172021A (en) * 2012-10-16 2019-11-12 Janssen Sciences Ireland Uc Rsv antiviral compounds
AU2014209853B2 (en) * 2013-01-28 2017-12-21 Janssen Sciences Ireland Uc Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents
CN105392787B (zh) * 2013-05-14 2017-11-24 豪夫迈·罗氏有限公司 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚
EP2997028A1 (en) 2013-05-14 2016-03-23 F.Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
HK1222855A1 (zh) * 2013-08-15 2017-07-14 F. Hoffmann-La Roche Ag 新的用於治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
AU2014308991B2 (en) 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
WO2015065336A1 (en) * 2013-10-29 2015-05-07 Medivir Ab Respiratory syncytial virus inhibitors
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
PE20170673A1 (es) * 2014-08-05 2017-05-22 Alios Biopharma Inc Terapia de combinacion para tratar una paramixovirus
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
DK3324977T3 (da) 2015-07-22 2022-10-17 Enanta Pharm Inc Benzodiazepinderivater som rsv-inhibitorer
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
CA3080138A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
BR112021018335A2 (pt) 2019-03-18 2021-11-23 Enanta Pharm Inc Derivados de benzodiazepina como inibidores de rsv
AU2020357452B2 (en) 2019-10-04 2026-01-29 Enanta Pharmaceuticals, Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
EP4165034A1 (en) 2020-06-11 2023-04-19 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
WO2022182861A1 (en) 2021-02-26 2022-09-01 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1436079A (zh) * 2000-06-13 2003-08-13 布里斯托尔-迈尔斯斯奎布公司 咪唑并吡啶和咪唑并嘧啶抗病毒剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514162A (ja) 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
AU1099000A (en) 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
IL147327A0 (en) 1999-06-28 2002-08-14 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors
SI1196408T1 (en) 1999-06-28 2005-02-28 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6506738B1 (en) 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1436079A (zh) * 2000-06-13 2003-08-13 布里斯托尔-迈尔斯斯奎布公司 咪唑并吡啶和咪唑并嘧啶抗病毒剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIANGDONG ALAN WANG: "Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途

Also Published As

Publication number Publication date
EA201390888A1 (ru) 2013-12-30
JP6005656B2 (ja) 2016-10-12
KR20140025321A (ko) 2014-03-04
CA2821999A1 (en) 2012-06-21
WO2012080446A1 (en) 2012-06-21
AU2011343255B2 (en) 2014-12-11
UA112298C2 (uk) 2016-08-25
IL225640A (en) 2015-02-26
CY1117751T1 (el) 2017-05-17
HRP20160650T1 (hr) 2016-07-15
ZA201304424B (en) 2014-12-23
ES2576180T3 (es) 2016-07-06
PT2651903E (pt) 2016-06-17
US20130267508A1 (en) 2013-10-10
NZ609450A (en) 2014-10-31
MX2013006886A (es) 2013-07-05
US8865705B2 (en) 2014-10-21
CN107417683A (zh) 2017-12-01
HK1247616A1 (zh) 2018-09-28
EP2651903A1 (en) 2013-10-23
TWI530495B (zh) 2016-04-21
MY156641A (en) 2016-03-15
EP2651903B1 (en) 2016-03-23
JP2013545785A (ja) 2013-12-26
HUE029247T2 (en) 2017-02-28
DK2651903T3 (da) 2016-06-27
AU2011343255A1 (en) 2013-05-02
SI2651903T1 (sl) 2016-07-29
BR112013012137A2 (pt) 2016-08-16
PH12013500796A1 (en) 2013-06-24
KR101876240B1 (ko) 2018-08-02
CL2013001713A1 (es) 2013-10-11
MX340030B (es) 2016-06-21
TW201305142A (zh) 2013-02-01
SG190766A1 (en) 2013-07-31
AR085203A1 (es) 2013-09-18
IL225640A0 (en) 2013-06-27
EA022972B1 (ru) 2016-03-31
CA2821999C (en) 2019-02-26
PL2651903T3 (pl) 2016-10-31

Similar Documents

Publication Publication Date Title
CN103313974A (zh) 苯并咪唑呼吸道合胞病毒抑制剂
CN103339128B (zh) 作为呼吸道合胞病毒抗病毒剂的氮杂吲哚
TWI515187B (zh) 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI527814B (zh) 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
US20150166533A1 (en) Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
JP6259451B2 (ja) Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
CN103328472A (zh) 作为呼吸道合胞病毒抗病毒剂的咪唑并吡啶
US20150175608A1 (en) Novel 4-substituted 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
JP2015519387A (ja) Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
HK1185065A (en) Benzimidazole respiratory syncytial virus inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1185065

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: IRELAND JANSSEN R + D COMPANY

Free format text: FORMER OWNER: JANSSEN R + D IRELAND

Effective date: 20150728

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150728

Address after: The Irish Village

Applicant after: Ireland Jansen scientific company

Address before: Kirk County, Ireland

Applicant before: Tibotec Pharm Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130918

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1185065

Country of ref document: HK